Kahan BD - Search Results

1

Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.

Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M, Slade JM; FTY720 Study Group. Tedesco-Silva H, et al. Among authors: kahan bd. Transplantation. 2006 Dec 27;82(12):1689-97. doi: 10.1097/01.tp.0000251718.95622.b3. Transplantation. 2006. PMID: 17198261 Clinical Trial.

2

FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.

Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. Tedesco-Silva H, et al. Among authors: kahan bd. Transplantation. 2004 Jun 27;77(12):1826-33. Transplantation. 2004. PMID: 15223899 Corrected and republished. Clinical Trial.

3

FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.

Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. Tedesco-Silva H, et al. Among authors: kahan bd. Transplantation. 2005 Jun 15;79(11):1553-60. Transplantation. 2005. PMID: 15940045 Clinical Trial.

4

FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.

Tedesco-Silva H, Lorber MI, Foster CE, Sollinger HW, Mendez R, Carvalho DB, Shapiro R, Rajagopalan PR, Mayer H, Slade J, Kahan BD; FTY720A2202 clinical study group. Tedesco-Silva H, et al. Among authors: kahan bd. Clin Transplant. 2009 Sep-Oct;23(5):589-99. doi: 10.1111/j.1399-0012.2009.01070.x. Epub 2009 Aug 27. Clin Transplant. 2009. PMID: 19719728 Clinical Trial.

5

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.

Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H; B251 Study Group. Lorber MI, et al. Transplantation. 2005 Jul 27;80(2):244-52. doi: 10.1097/01.tp.0000164352.65613.24. Transplantation. 2005. PMID: 16041270 Clinical Trial.

6

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.

Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C. Kovarik JM, et al. Among authors: kahan bd. Transplantation. 2002 Mar 27;73(6):920-5. doi: 10.1097/00007890-200203270-00016. Transplantation. 2002. PMID: 11923693 Clinical Trial.

7

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.

Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L. Kahan BD, et al. Transplantation. 2003 Oct 15;76(7):1079-84. doi: 10.1097/01.TP.0000084822.01372.AC. Transplantation. 2003. PMID: 14557756 Clinical Trial.

8

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.

Kahan BD, Rajagopalan PR, Hall M. Kahan BD, et al. Transplantation. 1999 Jan 27;67(2):276-84. doi: 10.1097/00007890-199901270-00016. Transplantation. 1999. PMID: 10075594 Clinical Trial.

9

Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.

Kovarik JM, Kahan BD, Rajagopalan PR, Bennett W, Mulloy LL, Gerbeau C, Hall ML. Kovarik JM, et al. Among authors: kahan bd. Transplantation. 1999 Nov 15;68(9):1288-94. doi: 10.1097/00007890-199911150-00012. Transplantation. 1999. PMID: 10573065 Clinical Trial.

10

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Kahan BD, et al. Transplantation. 1999 Nov 27;68(10):1526-32. doi: 10.1097/00007890-199911270-00016. Transplantation. 1999. PMID: 10589950 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

715 results

Search Page